Chemed (CHE) Cash & Equivalents (2009 - 2026)

Chemed has reported Cash & Equivalents for 18 years, with the latest figure at $16.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 90.31% year-over-year to $16.9 million; the trailing twelve-month figure through Mar 2026 stood at $16.9 million (down 90.31% YoY), and the FY2025 full-year result was $74.5 million, down 58.22% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $16.9 million, down from $74.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $313.3 million in Q1 2024, with the low at $7.8 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $139.0 million, with a median of $159.9 million recorded in 2023.
• Year-over-year, Cash & Equivalents plunged 91.36% in 2022 and jumped 2125.29% in 2023.
• Tracing CHE's Cash & Equivalents over 5 years: stood at $74.1 million in 2022, then soared by 256.09% to $264.0 million in 2023, then tumbled by 32.43% to $178.4 million in 2024, then plunged by 58.22% to $74.5 million in 2025, then tumbled by 77.38% to $16.9 million in 2026.
• The last three Cash & Equivalents figures came in at $16.9 million (Q1 2026), $74.5 million (Q4 2025), and $129.8 million (Q3 2025), per Business Quant data.

Peer Comparison